{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Truvada&page=2",
    "query": {
      "intervention": "Truvada",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Truvada&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-22T03:39:51.446Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02605954",
      "title": "Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "E/C/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "ABC/3TC",
          "type": "DRUG"
        },
        {
          "name": "Third Antiretroviral Agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 275,
      "start_date": "2015-11-18",
      "completion_date": "2018-01-24",
      "has_results": true,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-09-22T03:39:51.446Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02605954"
    },
    {
      "nct_id": "NCT02411630",
      "title": "Factors Affecting PrEP Adherence",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Emtricitabine/tenofovir disoproxil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "22 Years",
        "sex": "MALE",
        "summary": "15 Years to 22 Years · Male only"
      },
      "enrollment_count": 167,
      "start_date": "2013-06",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2017-02-28",
      "last_synced_at": "2026-09-22T03:39:51.446Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02411630"
    },
    {
      "nct_id": "NCT05457530",
      "title": "Doravirine and Weight Gain in Antiretroviral Naive",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Body Weight Changes",
        "Human Immunodeficiency Virus",
        "ART",
        "Obesity",
        "Minority Health",
        "BMD",
        "Metabolic Syndrome",
        "Fasting"
      ],
      "interventions": [
        {
          "name": "DOR/3TC/TDF",
          "type": "DRUG"
        },
        {
          "name": "DOR + FTC/TAF",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "BIC/FTC/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Prism Health North Texas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2022-08-01",
      "completion_date": "2023-05-03",
      "has_results": false,
      "last_update_posted_date": "2023-05-12",
      "last_synced_at": "2026-09-22T03:39:51.446Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05457530"
    },
    {
      "nct_id": "NCT03086200",
      "title": "Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Patient Adherence",
        "HIV Seronegativity"
      ],
      "interventions": [
        {
          "name": "brief Motivational Interviewing",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 263,
      "start_date": "2017-06-23",
      "completion_date": "2020-12-18",
      "has_results": false,
      "last_update_posted_date": "2021-09-13",
      "last_synced_at": "2026-09-22T03:39:51.446Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • San Diego, California • Torrance, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03086200"
    },
    {
      "nct_id": "NCT00949234",
      "title": "Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Prevention",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "tenofovir + emtricitabine, lopinavir/ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 267,
      "start_date": "2010-03",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2017-12-18",
      "last_synced_at": "2026-09-22T03:39:51.446Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00949234"
    },
    {
      "nct_id": "NCT04760691",
      "title": "Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV",
        "Prophylaxis",
        "Transgender"
      ],
      "interventions": [
        {
          "name": "Truvada alone",
          "type": "DRUG"
        },
        {
          "name": "Truvada plus Leuprolide 11.25mg intramuscular injection",
          "type": "DRUG"
        },
        {
          "name": "Truvada plus Estradiol 1 mg",
          "type": "DRUG"
        },
        {
          "name": "Truvada plus Estradiol 6 mg",
          "type": "DRUG"
        },
        {
          "name": "Estradiol 6 mg alone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 13,
      "start_date": "2021-03-01",
      "completion_date": "2025-03-24",
      "has_results": true,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-09-22T03:39:51.446Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04760691"
    },
    {
      "nct_id": "NCT01003990",
      "title": "Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "Atazanavir",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir/Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir/Emtricitabine",
          "type": "DRUG"
        },
        {
          "name": "Lopinavir/ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 710,
      "start_date": "2002-10",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2017-05-11",
      "last_synced_at": "2026-09-22T03:39:51.446Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01003990"
    },
    {
      "nct_id": "NCT03080597",
      "title": "PrEP for HBCUs (Study 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "At Risk for HIV"
      ],
      "interventions": [
        {
          "name": "PrEP Smart app",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "MALE",
        "summary": "18 Years to 30 Years · Male only"
      },
      "enrollment_count": 16,
      "start_date": "2017-03-01",
      "completion_date": "2018-10-01",
      "has_results": false,
      "last_update_posted_date": "2019-01-31",
      "last_synced_at": "2026-09-22T03:39:51.446Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03080597"
    },
    {
      "nct_id": "NCT05729568",
      "title": "A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "Teropavimab",
          "type": "DRUG"
        },
        {
          "name": "Zinlirvimab",
          "type": "DRUG"
        },
        {
          "name": "Lenacapavir Tablet",
          "type": "DRUG"
        },
        {
          "name": "Lenacapavir Injection",
          "type": "DRUG"
        },
        {
          "name": "Antiretroviral Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 83,
      "start_date": "2023-05-15",
      "completion_date": "2030-12",
      "has_results": true,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-09-22T03:39:51.446Z",
      "location_count": 29,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 25 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05729568"
    },
    {
      "nct_id": "NCT01005290",
      "title": "A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Combination pill",
          "type": "DRUG"
        },
        {
          "name": "Ramipril",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ferrer Internacional S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2009-10",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2012-07-26",
      "last_synced_at": "2026-09-22T03:39:51.446Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01005290"
    }
  ]
}